R

Roche

Global pharmaceuticals and diagnostics company

Medical Enabler

Full-TimeUpdated on 10/14/2026
No salary listed
Mid
PharmD, PhD, MD
Taipei City, Taiwan
In Person
Biology & Biotech

About the job

Requirements
  • An advanced clinical or science degree, such as an M.D., PharmD, or PhD, is required.
  • Professional experience within the pharmaceutical industry is required.
  • Knowledge of the overall drug development process relevant to pharmaceutical or biotechnology organizations is required.
  • Experience in developing and implementing clinical trials is required.
  • Experience in data analysis, interpretation, and assessing clinical relevance is required.
  • Experience writing clinical publications and delivering scientific presentations is required.
  • Strategic thinking, leadership, analytical skills, and results orientation are required.
  • Communication, interpersonal, networking, negotiation, and presentation skills are required.
  • Knowledge of data analysis and statistics, the relevant therapeutic area, ICH, GCP, local regulations, drug discovery and commercialization processes, and common computer skills is required.
  • Fluent written and verbal English is required.
  • Ability to work in a matrix organization and deliver high-standard work aligned with organizational needs and priorities is required.
  • Experience with internal and external engagement and creating strategies to inform and lead the organization is required.
  • Ability to communicate effectively at all levels to influence and inspire is required.
  • Ability to operate in a compliance-led regulatory environment and an autonomous working environment is required.
  • Ability to prioritize workload, analyze problems, devise tactics, gain support and consensus, and drive change is required.
  • Ability to solve issues affecting Medical Affairs and the wider business and deliver strategically aligned therapeutic-area priorities is required.
  • Ability to work with cross-functional teams, understand and leverage digital tools, and implement agile ways of working is required.
  • Ability to work in a self-managed team and coach or mentor peers using a VACC mindset is required.
Responsibilities
  • Develop and cultivate strategic relationships with therapeutic area experts and other healthcare influencers.
  • Translate insights into strategic, actionable recommendations for broad stakeholder groups to improve healthcare systems, including through co-creation.
  • Advise on, contribute to, or lead strategic planning and drive desired outcomes, accounting for patient needs, Taiwan-specific considerations, business needs, resource requirements, regulatory considerations, and market access.
  • Optimize clinical development throughout the product lifecycle to bring better treatments to patients.
  • Generate and communicate medical evidence to support healthcare decisions by practitioners, patients, and payers.
  • Initiate and implement medical or innovative projects, such as compassionate use programs, local access mechanisms, or digital solutions.
  • Share knowledge and resources transparently through networked ways of working to improve effectiveness and organizational impact.
  • Work with external partners and internal teams to identify unmet medical needs across the patient journey and support exceptional patient care.
  • Serve as a medical content expert in one or more therapeutic areas, build scientific partnerships with external partners, support access to products and clinical trials, and attend to patient safety and healthcare professionals’ needs.
  • Prioritize work, see projects through from conception to completion, and deliver solutions for healthcare systems.
Desired Qualifications
  • Relationships with external therapeutic area experts, other thought leaders, and external organizations are strongly preferred.
  • Awareness of theories, techniques, and technologies within Medical Affairs, such as data and insight generation, scientific partnerships, and digital educational engagement, is desirable.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.